
Sosei Heptares partners with a UK-based cancer research organization to bring its drug to trial
Cancer research has been a focus for Sosei Heptares for several years, and their latest deal hopes to progress one of their newer therapies.
On Friday, the Japanese company inked a deal with Cancer Research UK to bring one of its cancer drug candidates into the clinic. According to Sosei, the agreement will have Cancer Research UK run a Phase I/IIa trial of Sosei’s cancer candidate HTL00397322, an EP4 antagonist. The candidate will be evaluated as both a combination therapy and a monotherapy. While no exact financial details were given, Sosei will still hold the program’s license after the study reads out.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.